SYRE

Spyre Therapeutics Inc

Add to Watchlist

Advanced Chart

14.750

-0.180(-1.210%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

14.960

Open

14.960

VWAP

14.53

Vol

1.03M

Mkt Cap

890.22M

Low

14.132

Amount

15.04M

EV/EBITDA(TTM)

Total Shares

60.35M

492.08M

EV/OCF(TTM)

P/S(TTM)

Spyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. It has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.803

-0.88%

-0.729

-46.43%

-0.680

-20.93%

Estimates Revision

The market is revising No Change the revenue expectations for Spyre Therapeutics, Inc. (SYRE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -34.96%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-11.97%

In Past 3 Month

Stock Price

Go Down

-34.96%

In Past 3 Month

8 Analyst Rating

283.73% Upside

Wall Street analysts forecast SYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYRE is 56.60 USD with a low forecast of 27.00 USD and a high forecast of 71.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

283.73% Upside

Current: 14.750

Low

27.00

Averages

56.60

High

71.00

283.73% Upside

Current: 14.750

Low

27.00

Averages

56.60

High

71.00

Leerink Partners

Faisal Khurshid

Buy

Initiates

$45

2025-04-08

Reason

Leerink Partners

Faisal Khurshid

Price Target

$45

2025-04-08

Initiates

Buy

Reason

Jones Trading

Debanjana Chatterjee

Hold

Initiates

n/a

2024-12-11

Reason

Jones Trading

Debanjana Chatterjee

Price Target

n/a

2024-12-11

Initiates

Hold

Reason

Baird

Colleen Kusy

Buy

Maintains

$50 → $65

2024-11-13

Reason

Baird

Colleen Kusy

Price Target

$50 → $65

2024-11-13

Maintains

Buy

Reason

Baird raised the firm's price target on Spyre Therapeutics to $65 from $50 and keeps an Outperform rating on the shares. The firm said they posted better-than-expected initial data from SPY001 and thinks the data incrementally de-risks its lead asset and broad pipeline, which could offer best-in-class dosing and potentially improved efficacy in IBD.

Guggenheim

Yatin Suneja

Strong Buy

Maintains

$50 → $65

2024-10-25

Reason

Guggenheim

Yatin Suneja

Price Target

$50 → $65

2024-10-25

Maintains

Strong Buy

Reason

Wedbush

David Nierengarten

Buy

Initiates

$45

2024-09-04

Reason

Wedbush

David Nierengarten

Price Target

$45

2024-09-04

Initiates

Buy

Reason

Evercore ISI Group

Umer Raffat

Buy

Initiates

n/a

2024-07-16

Reason

Evercore ISI Group

Umer Raffat

Price Target

n/a

2024-07-16

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Spyre Therapeutics Inc (SYRE.O) is -4.94, compared to its 5-year average forward P/E of -4.86. For a more detailed relative valuation and DCF analysis to assess Spyre Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.86

Current PE

-4.94

Overvalued PE

-1.78

Undervalued PE

-7.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.11

Current EV/EBITDA

-2.01

Overvalued EV/EBITDA

0.60

Undervalued EV/EBITDA

-4.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

164.59

Current PS

0.00

Overvalued PS

547.55

Undervalued PS

-218.36

Financials

Annual

Quarterly

FY2025Q1

N/A

Total Revenue

FY2025Q1

YoY :

+12.13%

-53.57M

Operating Profit

FY2025Q1

YoY :

+2.09%

-44.77M

Net Income after Tax

FY2025Q1

YoY :

-38.33%

-0.74

EPS - Diluted

FY2025Q1

YoY :

+43.63%

-40.99M

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

N/A

FCF Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 2153.76% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

257.2K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 721.39% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.1M

Volume

6-9

Months

0.0

Volume

0-12

Months

131.3K

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.8M

Volume

Months

6-9

0.0

Volume

Months

0-12

17.6M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 2153.76% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

257.2K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SYRE News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

16:18:31

Spyre Therapeutics reports Q1 EPS (60c), consensus (84c)

2025-05-05 (ET)

2025-05-05

08:14:09

Spyre Therapeutics' SPY001 shows efficacy in two poster presentations

2025-03-27 (ET)

2025-03-27

16:08:38

Spyre Therapeutics says first patient dosed in Phase 1 trial of SPY003

News

9.0

05-05NASDAQ.COM

Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025

9.0

05-05PRnewswire

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

5.0

05-02Newsfilter

Spyre Therapeutics Announces Grants of Inducement Awards